Study S001276
A 26 Week Randomised, Parallel Three-arm, Open-label, Multi-centre, Multinational Treat-to-target Trial Comparing Fixed Ratio Combination of Insulin Degludec and Liraglutide Versus Insulin Degludec or Liraglutide Alone, in Subjects With Type 2 Diabetes Treated With 1-2 Oral Anti-diabetic Drugs (OADs)With a 26 Week Extension
Registration
Registered primary outcomes
- Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26. [Week 0, week 26]
Linked records (10)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0010237 | Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Natale P, The Cochrane database of systematic reviews | 2025 | Systematic review | PMID 39963952DOI | cites ClinicalTrials.gov:NCT01336023; registry reference DERIVED:39963952 |
| R0050295 | 75-OR: In-Silico Replay of Insulin Degludec and Liraglutide Clinical Trial Data in Subjects with Type 2 Diabetes MOHAMMADREZA GANJIARJENAKI, Diabetes | 2024 | Other trial | DOI | cites ClinicalTrials.gov:NCT01336023 |
| R0015570 | Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Norwood P, Diabetes, obesity & metabolism | 2017 | Other | PMID 28417535DOI | registry reference RESULT:28417535 |
| R0017641 | Efficacy and Safety of IDegLira in Participants with Type 2 Diabetes in India Uncontrolled on Oral Antidiabetic Drugs and Basal Insulin: Data from the DUAL Clinical Trial Program. Khunti K, Diabetes therapy : research, treatment and education of diabetes and related disorders | 2017 | Other trial | PMID 28332144DOI | cites ClinicalTrials.gov:NCT01336023; registry reference BACKGROUND:28332144 |
| R0020281 | A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. King AB, Diabetes technology & therapeutics | 2017 | Randomized trial | PMID 28282219DOI | cites ClinicalTrials.gov:NCT01336023; registry reference RESULT:28282219 |
| R0021084 | Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given Alone. Vilsbøll T, Clinical drug investigation | 2016 | Other | PMID 26894800DOI | registry reference RESULT:26894800 |
| R0014347 | Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. Kapitza C, Journal of clinical pharmacology | 2015 | Randomized trial | PMID 25998481DOI | registry reference RESULT:25998481 |
| R0018262 | IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test. Holst JJ, Journal of diabetes science and technology | 2015 | Randomized trial | PMID 26443290DOI | cites ClinicalTrials.gov:NCT01336023; registry reference RESULT:26443290 |
| R0021244 | One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Gough SC, Diabetes, obesity & metabolism | 2015 | Randomized trial | PMID 25980900DOI | registry reference RESULT:25980900 |
| R0016819 | Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Gough SC, The lancet. Diabetes & endocrinology | 2014 | Randomized trial | PMID 25190523DOI | cites ClinicalTrials.gov:NCT01336023; registry reference RESULT:25190523 |